KBC Group
IBRX icon

KBC Group’s ImmunityBio IBRX Stock Holding History

KBC Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79K Buy
+10,307
New +$70.6K ﹤0.01% 1459

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

KBC Group's IBRX Position: Q1 2026 in Review

KBC Group opened a new position in ImmunityBio (IBRX) in Q1 2026: 10,307 shares worth $79K. The stake represents ﹤0.01% of the portfolio and ranks #1459 among its holdings.

386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • KBC Group held 10,307 shares of ImmunityBio worth $79K as of Q1 2026.
  • ImmunityBio was a new KBC Group position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1459 holding.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.